2020
Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers.
Foldi J, Schnabel C, Salganik M, Pusztai L, Sanft T. Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers. Journal Of Clinical Oncology 2020, 38: 527-527. DOI: 10.1200/jco.2020.38.15_suppl.527.Peer-Reviewed Original ResearchLate distant recurrenceAdjuvant endocrine therapyEndocrine therapyDistant recurrenceDXA scansBreast cancerHigh riskStage IEarly-stage hormone receptorExtended endocrine therapyIntolerable side effectsOsteopenia/osteoporosisPositive breast cancerRate of adherenceSerious adverse effectsBreast cancer recurrenceMajority of ptsHigher likelihoodElectronic health recordsLocal recurrenceMedian ageLate recurrenceMetastatic recurrenceTumor characteristicsMedication adherence
2011
Who provides ongoing care to breast cancer survivors and does it make a difference?
Sowden M, Sanft T, Chagpar A. Who provides ongoing care to breast cancer survivors and does it make a difference? Journal Of Clinical Oncology 2011, 29: 199-199. DOI: 10.1200/jco.2011.29.27_suppl.199.Peer-Reviewed Original ResearchBreast cancer survivorsClinical breast examCancer survivorsOngoing careNational Health Interview SurveyHealth Interview SurveyQuality of careSignificant differencesProvider choicePaucity of dataSurvivorship plansMedian ageSurvivorship periodSurveillance recommendationsBreast examMean agePrimary careFamily physiciansProvider typeSUDAAN softwareVariety of providersMultiple specialtiesSurvivorsInterview SurveyCare